Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Centre Hospitalier Universitaire de Bordeaux (CHU de Bordeaux); Centre hospitalier de Pau; Service Hématologie - IUCT-Oncopole CHU Toulouse; Pôle Biologie CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Hôpital Ambroise Paré AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay; AP-HP - Hôpital Cochin Broca Hôtel Dieu Paris; Université Paris Cité (UPCité); Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); Hôpital Henri Mondor; Centre Léon Bérard Lyon; Hôpital de la Timone CHU - APHM (TIMONE); CHU Amiens-Picardie; Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); Hôpital Avicenne AP-HP; Service de Dermatologie et Allergologie CHRU Nancy; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Service de dermatologie Strasbourg; Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg); Les Hôpitaux Universitaires de Strasbourg (HUS)-Les Hôpitaux Universitaires de Strasbourg (HUS); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); AP-HP - Hôpital Bichat - Claude Bernard Paris; CHU Dijon; Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon); CHU Montpellier; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Université de Lille; Hopital Saint-Louis AP-HP (AP-HP); Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL); Centre Léon Bérard Lyon -Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Hospices Civils de Lyon (HCL); BoRdeaux Institute in onCology (Inserm U1312 - BRIC); Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM); CHU Bordeaux
    • بيانات النشر:
      HAL CCSD
      Wiley
    • الموضوع:
      2024
    • Collection:
      Université de Versailles Saint-Quentin-en-Yvelines: HAL-UVSQ
    • نبذة مختصرة :
      International audience ; Background: Cutaneous adnexal carcinomas are a heterogeneous group of rare neoplasms. Surgical excision is the first-line treatment in localized stage. The use and effectiveness of radiotherapy have not been thoroughly evaluated in these neoplasms.Objectives: The present work analyses prognostic factors on outcomes in skin adnexal carcinomas, based on data from the CARADERM (CAncers RAres DERMatologiques) database.Methods: Data were collected retrospectively including demographic data, tumour types and therapeutic characteristics of all patients included in the CARADERM database, with at least one informative follow-up visit. Analyses were performed on three populations: patients with complete resection of the primary tumour (ADJ/primary population), patients achieving complete remission after complete resection of a recurrent tumour (ADJ/recurrent population) and patients with unresectable locally advanced or metastatic tumours (ADV/MET population). Overall and recurrence/progression-free survivals at 3-year were analysed using Cox regression models.Results: Radiotherapy did not affect overall survival (OS) in the ADJ/primary population. Adjusted recurrence-free survival (RFS) was significantly lower in the radiotherapy group in ADJ/primary group. Older patients had significantly poorer OS and RFS. Tumour size and immunosuppression were significantly associated with poorer RFS only. Radiotherapy had no effect on OS and RFS in the ADJ/recurrent population. Age was the only factor associated with a poorer OS. Radiotherapy was significantly associated with longer progression-free survival (PFS) in age-sex adjusted analysis in the ADV/MET population, without effect on OS.Conclusions: Our study shows that age, tumour size and immunosuppression are significantly associated with survival in localized adnexal carcinomas. Radiotherapy may improve PFS in the ADV/MET population but not in localized and recurrent carcinomas after complete excision.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/38864258; hal-04626767; https://hal.science/hal-04626767; https://hal.science/hal-04626767/document; https://hal.science/hal-04626767/file/Acad%20Dermatol%20Venereol%20-%202024%20-%20Zagala%20-%20Radiotherapy%20and%20prognostic%20factors%20in%20adnexal%20carcinomas%20A%20retrospective%20study.pdf; PUBMED: 38864258
    • الرقم المعرف:
      10.1111/jdv.20155
    • Rights:
      http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.26750E52